


NSW colonoscopy categorisation

AUGUST 2020



Agency for Clinical Innovation

67 Albert Avenue
Chatswood NSW 2067

PO Box 699 Chatswood NSW 2057
T +61 2 9464 4666 | F +61 2 9464 4728
E aci-info@health.nsw.gov.au | www.aci.health.nsw.gov.au

Produced by: Gastroenterology Network

Further copies of this publication can be obtained from the Agency for Clinical Innovation website at www.aci.health.nsw.gov.au

Disclaimer: Content within this publication was accurate at the time of publication.

This work is copyright. It may be reproduced in whole or part for study or training purposes subject to the inclusion of an acknowledgment of the source. It may not be reproduced for commercial usage or sale. Reproduction for purposes other than those indicated above, requires written permission from the Agency for Clinical Innovation.

Preferred citation: *NSW Agency for Clinical Innovation. NSW colonoscopy categorisation.*
Sydney: ACI; 2020.

SHPN (ACI) 200493
ISBN 978-1-76081-457-1 (print); 978-1-76081-458-8 (online)

Version: V2; ACI_0321 [08/20] Date amended: August 2020

Cover image credit: Shutterstock.com

Trim: ACI/D20/659

© State of New South Wales (NSW Agency for Clinical Innovation) 2020.
Creative Commons Attribution No derivatives 4.0 licence.

Contents


NSW colonoscopy categorisation at a glance	1
Section 1: Guide overview	2
Section 2: Colonoscopy categorisation criteria	3
Section 3: Explanatory notes	5
References	11
Glossary	12
Acknowledgements	13

NSW colonoscopy categorisation at a glance

This Guide reflects the patient’s journey from the point in time a colonoscopy has been agreed as the preferred investigation/treatment option by the patient and GP.

Patients who require urgent intervention are excluded from the scope of this Guide.

Figure 1. NSW public health colonoscopy pathway



Section 1: Guide overview

High quality, timely colonoscopy is critical to the early detection and treatment of bowel cancer and other gastrointestinal conditions. Increasing demand for colonoscopy services has led to the need for criteria for the categorisation and prioritisation of patients presenting to NSW public hospital colonoscopy services.

The *NSW Colonoscopy Categorisation Clinical Practice Guide* aims to aid clinicians who receive colonoscopy referrals in triaging patients.

It is intended to support gastroenterologists, surgeons, general practitioners (GPs), clinical nurse consultants, GP endoscopists and waiting list managers to appropriately manage colonoscopy services. It aims to:

- assist gastroenterologists, colorectal surgeons and GP surgeons in the prioritisation of colonoscopy bookings
- align with the implementation of the direct access colonoscopy initiative that is part of the state's Leading Better Value Care program.

Three priority categories

There are three clinical priority categories for patients who require a colonoscopy. Each category has a defined period within which patients should receive colonoscopy:

- Category 1: within 30 days
- Category 2: within 90 days
- Category 3: within 365 days.#

Referred patients are assessed in terms of critical factors (e.g. positive immunochemical faecal occult blood test (+iFOBT); unexplained anaemia and rectal bleeding) and patient characteristics (e.g. age) for allocation to one of these categories (Table 1).

Methods

This document is a revision of the *Colonoscopy Categorisation Guide (2007)*. Its production was led by the Gastroenterology Network Colonoscopy Categorisation Working Party of the Agency for Clinical Innovation (ACI), with the support of the Cancer Institute NSW, Ministry of Health and other key stakeholders (see *Acknowledgements*, page 13).

In 2018, the Cancer Institute NSW held a workshop on improving public colonoscopy access after a +iFOBT. The workshop demonstrated that NSW lacked specific guidance on how clinical criteria are applied to colonoscopy classifications and waiting times.

The guide does not replace local decision-making processes and should be underpinned by local models of care. It is understood that each local health district (LHD) will be responsible for its own implementation protocols.

Although the categories align with the *NSW Health Waiting Time and Elective Surgery Policy Directive PD2012_011*, the guidance in this document is based on a review of evidence and broad clinical input.

Section 2: Colonoscopy categorisation criteria

Table 1. NSW Colonoscopy categorisation criteria

Factor	Category 1: <30 days	Category 2: <90 days	Category 3: <365 days (surveillance)
NSW Ministry of Health definition of category	Procedure within 30 days desirable for a condition that has the potential to deteriorate quickly to the point that it may become an emergency OR admission within 30 days. High likelihood of significant organic pathology. Admission within 30 days desirable for conditions likely to deteriorate.	Procedure within 90 days desirable for a condition which is not likely to deteriorate quickly or become an emergency OR admission within 90 days lower likelihood of significant organic pathology or deterioration.	Patients who are unlikely to deteriorate quickly and which have little potential to become an emergency OR staged patients: Planned patients where a patient requires treatment periodically. <i>A Not Ready for Care patient is a patient who is not available to be admitted to hospital until some future date, and is Staged – not ready for clinical reasons.</i> The definition of staged from the wait time and elective surgery policy can be found in the <i>NSW Health Waiting Time and Elective Surgery Policy Directive PD2012_011</i> .
1. +iFOBT	Clinically appropriate +iFOBT	Other +iFOBT [#]	
2. Unexplained iron deficiency or unexplained anaemia	Unexplained iron deficiency OR unexplained anaemia AND EITHER any other critical factor* OR one or more other symptoms	Iron deficiency with no critical factors* or other symptoms (any age)	
3. Rectal bleeding	Rectal bleeding AND any one of: <ul style="list-style-type: none"> any other critical factor* <12 months duration, age ≥50 years <12 months with one or more other symptom, age <50 years 	Rectal bleeding <12 months duration AND no other critical factor* or other symptom AND age <50 years (note: Local investigation may be appropriate)	Rectal bleeding >12 months
4. Altered bowel habit	Altered bowel habit (>6 weeks and <12 months) AND any critical factor*	Altered bowel habit (>6 weeks and <12 months) AND no critical factor*	
5. Unexplained abdominal pain	Unexplained abdominal pain AND any critical factor*	Unexplained abdominal pain AND no critical factor*	
6. Unexplained significant weight loss	Unexplained significant weight loss AND any critical factor*	Unexplained weight loss AND no critical factor NOTE: Weight loss is not indicated for no critical factor* + symptoms + normal examination + normal MCH/MCV/iron studies	

Factor	Category 1: <30 days	Category 2: <90 days	Category 3: <365 days (surveillance)
7. Mass	Palpable rectal or abdominal mass OR mass present on rigid/flexible sigmoidoscopy OR likely colorectal mass on imaging		
8. Adenocarcinoma of unknown primary	Adenocarcinoma of unknown primary		
9. Colorectal cancer surveillance (post colon cancer resection)		Post colorectal resection with incomplete colonoscopy or incomplete clearance of polyps preoperatively. Complete examination of colon (if not done preoperatively)	Family history or personal history (refer to current <i>National Health & Medical Research Council (NHMRC) Clinical Practice Guidelines for Surveillance Colonoscopy</i> (section: <i>Colonoscopy after curative resection for colorectal cancer</i>))
10. Polyp management and surveillance	Polyps requiring referral for excision or incomplete polypectomy requires surveillance as per <i>NHMRC Clinical Practice Guidelines for Surveillance Colonoscopy</i>		Surveillance colonoscopy after polypectomy (refer to current <i>NHMRC Clinical Practice Guidelines for Surveillance Colonoscopy</i> (section: <i>Colonoscopic surveillance after polypectomy</i>))
11. Suspected inflammatory bowel disease (IBD)	Suspected IBD AND any one of: <ul style="list-style-type: none"> • any critical factor* or other symptom • calprotectin (+) • raised C-reactive protein or erythrocyte sedimentation rate • iron deficiency • low albumin • abnormal rigid/flexible sigmoidoscopy 		Surveillance procedure (refer to current <i>NHMRC Clinical Practice Guidelines for Surveillance Colonoscopy</i> (section: <i>Colonoscopic surveillance and management of dysplasia in inflammatory bowel disease</i>))

* Critical factors: +iFOBT, unexplained anaemia, rectal bleeding, age ≥ 60 .

E.g. +iFOBT in a <50-year-old patient without other critical factors or other symptoms.

Section 3: Explanatory notes

Assessment prior to colonoscopy referral

The GP must complete an adequate assessment prior to referral for colonoscopy. The assessment could include:

- taking a history of symptoms
- relevant medical background information, including current medications
- physical examination
- appropriate investigations (full blood count, ferritin, iFOBT in the symptomatic patient)
- prior colonoscopy reports and histology if available.

Colonoscopy clinical priority categorisation process

A clinical priority category is part of the Recommendation for Admission (RFA) form.

The RFA should include the proposed Medicare Benefits Schedule (MBS) item number to facilitate billing and audit. Investigations that have guided the assignment of a clinical priority category should be attached to the RFA.

Current NSW colonoscopy categories 1, 2 and 3 relate to procedures that are clinically recommended within 30, 90, or 365 days respectively from the date of receiving the RFA/referral for colonoscopy.

Table 2. Clinical priority categories

Clinical priority category	
A clinical assessment of the priority with which a patient requires elective admission [#]	
Category 1	Procedure clinically indicated within 30 days
Category 2	Procedure clinically indicated within 90 days
Category 3	Procedure clinically indicated within 365 days

[#] Patients requiring urgent intervention are outside the scope of this Guide.

The date stamped on the RFA by the receiving booking officer is the date used for waiting list registrations. This is the listing date and is the commencement of the waitlist period. This is in alignment with the *NSW Health Waiting Time and Elective Surgery Policy Directive PD2012_011*. Allocation of colonoscopy dates is ideally undertaken by the hospital to ensure equity of access between patients referred from the outpatient clinic and patients referred directly from private consultation rooms.

Categorisation of patients according to the Guide can be carried out by clinicians with the necessary expertise. This may be gastroenterologists, surgeons, GP endoscopists, GPs or clinical nurse consultants. Waiting list managers with appropriate clinical expertise may also be involved in the categorisation process.

Patients identified as requiring urgent colonoscopy can be escalated and would require emergency admission, for example impending large bowel obstruction. The management of these patients is outside the scope of this Guide.

Rationale for multiple colonoscopy timeframes

The requirement for colonoscopy within 30 days (Category 1) is supported by evidence that suggests that there is a low risk for change in cancer stage when the colorectal cancer is identified in this timeframe.¹

There are multiple clinical scenarios, including iFOBT, where the clinical priority category needs to be identified.

Time elapses from the patient receiving the referral from the GP, to the review and categorisation by the colonoscopist, to the final submission of the RFA. The potential psychological impact of waiting for a test to exclude cancer has been considered in the development of the Guide.

Surveillance colonoscopy categorisation

For guidance on surveillance colonoscopy, refer to *Clinical Practice Guidelines for Surveillance Colonoscopy (2019)*, which are approved by the National Health and Medical Research Council.²

Patients referred for surveillance colonoscopy prior to the recommended interval should be assessed for the presence of new symptoms, laboratory abnormalities, previous colonoscopy quality (if available) and family history. In the absence of new findings or other factors, these patients should be referred back to their GP for monitoring and scheduled for a colonoscopy at an appropriate time in the future.

The surveillance period may vary depending on the quality of a previous colonoscopy (for example, taking into account the quality of preparation or colonoscopist's performance).

Critical factors

Patients who have been referred for possible colonoscopy are assessed on critical factors and other symptoms.

The following critical factors support the clinician in the colonoscopy categorisation process.

Clinically appropriate +iFOBT

In addition to the recognised use of iFOBT for screening, evidence suggests that the addition of an iFOBT may be useful in the assessment of symptomatic patients.^{1, 3-5} Therefore, a +iFOBT will prioritise symptomatic patients to Category 1 (<30 days). Conversely, a -iFOBT may reduce the urgency in symptomatic patients.

While a +iFOBT suggests clinical categorisation Category 1, Category 2 or 3 may be allocated after clinical review. For example, +iFOBT in a <50 year old patient without other critical factors or other symptoms would likely be allocated Category 2 (<90 days) with a prioritised pathway.

Unexplained anaemia

Anaemia has been shown to have a positive predictive value (PPV) for colorectal cancer of 9.7% (3.5-27).⁶ This association is not restricted to iron deficiency anaemia.

Rectal bleeding

Rectal bleeding alone has a PPV of ~2.4% for colorectal cancer.⁷ Colorectal cancer risk is increased further if other factors are present, such as advanced age or new onset of bleeding. The exact nature of the bleeding is subjective (for example, cancer is thought to be more likely if the blood is darker). This Guide considers all rectal bleeding.

The role of digital rectal examination in categorisation is debated. Consider digital rectal examination for patients with rectal bleeding for whom a delay in colonoscopy is anticipated.

In a patient with prolonged (>12 months) bright red rectal bleeding without other symptoms, it may be reasonable to perform sigmoidoscopy and treat an underlying cause (such as haemorrhoids) if found, before embarking upon full colonoscopy. The clinician should explain to the patient that additional causes, such as cancer, might be present and have not been excluded. There should be very close observation/ follow-up by the treating doctor.

Age ≥60 years

Age is an independent risk factor for colorectal cancer, but it is noted that colorectal cancer does occur in young patients. Young patients often present late because of the incorrect belief that colorectal cancer is an 'old person's disease'.

The increased risk curvilinear, with an upwards inflection at 50-65 years of age.⁸

Other symptoms may include:

- altered bowel habit
- unexplained abdominal pain
- unexplained weight loss.

Clinical scenarios

These clinical scenarios present examples of critical factors and other symptoms.

CLINICAL SCENARIO 1. **Clinically appropriate +iFOBT**

Adverse change in stage of colorectal cancer at diagnosis with a delayed colonoscopy suggests that +iFOBT should prioritise patients to Category 1 (< 30 days).^{1, 3-5}

+iFOBT is the currently recommended screening stool test for the detection of colorectal cancer with a sensitivity of 79% (69-86) and specificity of 94% (92-95).^{1, 3-5}

The negative predictive value of -iFOBT is somewhat reassuring, at about 99%.⁹ The presence of a -iFOBT does not eliminate the possibility of colorectal cancer and should not rule out colonoscopy, particularly if other critical factors or symptoms are present. A -iFOBT however, may change the prioritisation category.

Note

- iFOBT is not appropriate in the presence of rectal bleeding.
- The iFOBT does not test for upper gastrointestinal blood loss.

CLINICAL SCENARIO 2.

Unexplained iron deficiency or unexplained anaemia

Alternative explanations for iron deficiency or anaemia should be considered and possibly treated prior to referral for colonoscopy.

If a cause for iron deficiency or anaemia is not identified, or if treatment has not been successful, then the patient should be referred for consideration of colonoscopy.¹⁰ Prioritisation will depend on critical factors or other symptoms.¹¹

Unexplained anaemia has been shown to have a PPV for colorectal cancer of 9.7% (3.5-27).⁷ This association is not restricted to iron deficiency. In one study 18% of patients with colorectal cancer had normocytic anaemia.¹³

Transferrin saturation has been shown to be inversely associated with colorectal cancer at diagnosis. Ferritin may be elevated as an acute phase reactant, especially in advanced colorectal cancer.¹³

CLINICAL SCENARIO 3.**Rectal bleeding**

Rectal bleeding is a strong predictor of colorectal cancer¹⁴ and a critical factor. Colonoscopy should be performed for bleeding not previously investigated or new onset or new pattern of rectal bleeding.

Rectal bleeding alone has a PPV of ~2.4% for colorectal cancer.⁷ The likelihood of colorectal cancer is increased further if additional critical factors or other symptoms are present, such as advanced age, change in bowel habit or weight loss. Colorectal cancer is said to be more likely if the bleeding is darker and/or mixed with mucus, but since this distinction is somewhat subjective this Guide considers all rectal bleeding.

The role of digital rectal examination is debated. It should be considered in the patient presenting with rectal bleeding in whom delay for further investigation is anticipated.

Rectal bleeding that has been present for >12 months and in the absence of any other signs or symptoms is unlikely to be due to colorectal cancer.

CLINICAL SCENARIO 4.**Altered bowel habit**

Altered bowel habit is any change from the patient's usual pattern of bowel motions. Examples are diarrhoea, constipation or a feeling of incomplete evacuation persisting longer than six weeks.

Defining significantly altered bowel habit requires clinical judgement. Changes for <6 weeks may be related to other factors, such as infection, dietary change, stress or new medications. Changes (especially constipation) present for >12 months are unlikely related to colorectal cancer. The presence of critical factors or other symptoms may lead to a change in prioritisation category.

Additional tests may be obtained to help estimate the priority, as this presentation can have a large differential diagnosis. iFOBT, full blood count and faecal calprotectin may contribute to the estimate of urgency to colonoscopy.

CLINICAL SCENARIO 5.**Unexplained abdominal pain**

There is a range of other abdominal and non-abdominal conditions that may explain abdominal pain. Therefore the term 'unexplained' is central to the consideration of this scenario.

Clinical judgement is important when assessing patients presenting with abdominal pain. Abdominal pain has a PPV for colorectal cancer of 3.3% (0.7–16%).¹²

Frequent episodes of pain and a history of <12 months have been associated with a greater likelihood of colorectal cancer.¹²

CLINICAL SCENARIO 6.**Unexplained weight loss**

Weight loss alone is a poor predictor of colorectal cancer (PPV 1.2%)¹² but is important in the presence of other symptoms¹⁴. The degree and recency of weight loss described in the literature is inconsistent.

CLINICAL SCENARIO 7.**Palpable mass or mass on imaging possibly explained by colorectal cancer**

A suspected colorectal cancer identified by examination or imaging the mass will prioritise patients to Category 1 (<30 days).

CLINICAL SCENARIO 8.**Adenocarcinoma of unknown origin**

Colorectal cancer is unlikely to be the cause in the absence of critical factors or other symptoms. Other investigations such as cross-sectional imaging or PET should precede colonoscopy.

CLINICAL SCENARIO 9.**Colorectal cancer surveillance**

Surveillance pertains to three situations:

1. Full colonoscopy if incomplete prior to colorectal cancer resection
2. Clearance of the colon of known polyps which were not removed prior to colorectal cancer resection
3. Ongoing surveillance after colorectal cancer resection, as per the *Clinical Practice Guidelines for Surveillance Colonoscopy*.²

CLINICAL SCENARIO 10.**Colorectal polyp management and surveillance**

Some patients have a known polyp that has not been completely removed due to size or complexity. Refer to guidance on surveillance post-polypectomy – see the *Clinical Practice Guidelines for Surveillance Colonoscopy*.²

CLINICAL SCENARIO 11.**Suspected inflammatory bowel disease (IBD)**

Patients with suspected IBD require colonoscopy for biopsy confirmation of diagnosis, assessment of extent of disease or response to therapy. Differentiation from other aetiologies such as infection or irritable bowel syndrome may be supported by history, physical examination and other investigations. These investigations include faecal calprotectin, faecal pathogens, full blood count and C-reactive protein (CRP) test.¹⁵

CLINICAL SCENARIO 12.**Surveillance**

Refer to the National Health & Medical Research Council (NHMRC) endorsed *Clinical Practice Guidelines for Surveillance Colonoscopy*.²

References

1. Cubiella J, Castro I, Hernandez V, et al. Diagnostic accuracy of fecal immunochemical test in average- and familial-risk colorectal cancer screening. *United European Gastroenterol J*. 2014;2(6):522–529. doi:10.1177/2050640614553285
2. Parente, F. et al. (2012) A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study. *Eur J Gastroenterol Hepatol* 24, 1145-1152, doi:10.1097/MEG.0b013e328355cc79 (2012).
3. Oono, Y. et al. (2010) A retrospective study of immunochemical fecal occult blood testing for colorectal cancer detection. *Clin Chim Acta* 411, 802-805, doi:10.1016/j.cca.2010.02.057 (2010).
4. Vega, P., Valentin, F. & Cubiella, J. (2015) Colorectal cancer diagnosis: pitfalls and opportunities. *World J Gastrointest Oncol* 7, 422-433,
5. McDonald, P. J. et al. (2013) Low faecal haemoglobin concentration potentially rules out significant colorectal disease. *Colorectal Dis* 15, e151-159, doi:10.1111/codi.12087.
6. Adelstein, B. A. et al. (2011) Most bowel cancer symptoms do not indicate colorectal cancer and polyps: a systematic review. *BMC Gastroenterol* 11, 65, doi:10.1186/1471-230X-11-65
7. Lin JS1, Piper MA1, Perdue LA1, Rutter C1, Webber EM1, O'Connor E1, Smith N1, Whitlock EP1. (2016) Screening for Colorectal Cancer: A Systematic Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jun. Report No.: 14-05203-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.
8. M Astin; T Griffin, R Neal et al (2011) The diagnostic value of symptoms for colorectal cancer in primary care: a systematic review. *Br J Gen Pract*. 2011 May; 61(586): e231–e243 Published online 2011 Apr 26. doi: 10.3399/bjgp11X572427
9. The Evaluation of Premenopausal Women with Anemia: What Is the Yield of Gastrointestinal Endoscopy *Digestive Diseases and Sciences (Dig Dis Sci.)*10; August 2009, Volume 54, Issue 8, pp 1667–1671
10. Salah H Elsafi,1 Norah I Alqahtani,1 Nawaf Y Zakary,2 and Eidan M Al Zahrani3 (2015) The sensitivity, specificity, predictive values, and likelihood ratios of fecal occult blood test for the detection of colorectal cancer in hospital settings *Clin Exp Gastroenterol*. 2015; 8: 279–284.
11. Explanatory notes for the Colonoscopy categorisation guidelines (2017). p 6. Victorian State Government, Department of Health and Human Resources. Accessed 6/7/2019
12. J Storm, G Rafferty (2013). Colorectal cancer presenting with anaemia. *BMJ Journals | Gut > Suppl_2* .https://gut.bmj.com > content.
13. Yu-Yao Chang, Jeng-Kai Jiang Shih-Ching Chang, Jen-Kou Lin, Chi-Jung Huang and Shung-Haur Yang (2018) Progressive Iron Deficiency with Advancing Stage in Colorectal Cancer Patients. *Clinics in Surgery*. Volume 3 .OPEN ACCESS levels: <http://clinicsinsurgery.com/Clinics in Surgery>.
14. Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, Clar C, Johnston R. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. *Health Technol Assess*. 2013;17(55): 1-211
15. NHMRC Clinical Practice Guidelines for Surveillance Colonoscopy. Updated March 2019. https://wiki.cancer.org.au/australia/Guidelines:Colorectal_cancer/Colonoscopy_surveillance See section: Colonoscopy after curative resection for colorectal cancer. Cited 20/1/2020
16. Cancer Research UK. <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence>

Glossary

Colonoscopy	Diagnostic/therapeutic examination of the colon with a colonoscope
CCSG	Colonoscopy Categorisation Steering Group
CCWG	Colonoscopy Categorisation Working Group
CPC	Clinical priority category
CRC	Colorectal cancer
CRP	C-reactive protein
DAC	Direct access colonoscopy, a clinical initiative of the Leading Better Value Care program
IBD	Inflammatory bowel disease
IDA	Iron deficiency anaemia
iFOBT	Immunochemical faecal occult blood test (also known as faecal immunochemical test or FIT).
LHD	Local health district
MCH	Mean corpuscular hemoglobin
MCV	Mean corpuscular volume
NHMRC	National Health & Medical Research Council
PET	Positron emission tomography
PPV	Positive predictive value
RFA	Request for admission
Screening	Investigation of an individual at standard risk of a condition, usually defined as a single time-point
Surveillance	The longitudinal investigation of an individual with respect to a condition. The use of this term in colorectal cancer usually implies increased risk for that individual
the Guide	NSW Colonoscopy Categorisation Clinical Practice Guide

Acknowledgements

The ACI gratefully acknowledges the following people who contributed to this Guide:

Colonoscopy Categorisation Working Group

A/Prof. Ian Norton – Chair
Gastroenterologist/Head of Dept.
Royal North Shore Hospital

Dr Matthew Hall
Deputy Chair Gastroenterologist/
Head of Dept,
Sutherland Hospital, SESLHD

Prof Jon Gani
Surgeon/Head of Dept.
John Hunter Hospital,
Hunter New England LHD

Dr Bruce Hodge
Colorectal Surgeon,
Port Macquarie Hospital,
Mid North Coast LHD

Dr John Barker
General Surgeon,
Hunter New England LHD

A/Prof Thomas Lee
Gastroenterologist,
Wollongong Hospital

Dr David Whitaker
Gastroenterologist,
Lismore Hospital

Dr Kenneth Koo
Gastroenterologist,
Liverpool Hospital

Dr Michael Bourke
Gastroenterologist,
Westmead Hospital

Dr Darryl Mackender
Gastroenterologist,
Orange Hospital

Dr Michael Payne
General Surgeon,
Murrumbidgee LHD

Dr Neil Wright
Head of Surgery,
Moruya Hospital

Dr Cameron Bell
Gastroenterologist,
Royal North Shore Hospital

Prof Peter Katelaris
Gastroenterologist,
Concord Hospital

A/Prof Martin Weltmann
Gastroenterologist/Head of Dept,
Nepean-Blue Mountains

Dr Martin Grehan
Gastroenterologist,
Nepean Blue Mountains Hospital

Dr Viraj Kariyawasam
Gastroenterologist,
Blacktown and Mt Druitt Hospitals

Cancer Institute NSW

Christopher Horn
NSW Bowel Cancer Screening
Program Manager

Sarah McGill
Director, Cancer Screening
and Prevention

Blythe O'Hara
Project Consultant

Brooke Selby
Leading Better Value Care
Direct Access Colonoscopy
Implementation Lead

NSW Ministry of Health

Melinda Pascoe
Principal Policy Officer
– Surgical Services,

Vincent Salomon
Senior Policy Officer,
System Purchasing Branch

External advice

Gastroenterology Network members

Prof Anne Duggan
Australian Commission on Safety
and Quality in Healthcare
Commission

Prof. Jon Emery
Herman Professor of Primary Care
Cancer Research, University of
Melbourne and Western Health

Dr Darren Pavey
Gastroenterology Network Co-Chair
and Gastroenterologist

Secretariat

Ingrid Klobasa
ACI Gastroenterology
Network Manager

The Agency for Clinical Innovation (ACI) is the lead agency for innovation in clinical care.

We bring consumers, clinicians and healthcare managers together to support the design, assessment and implementation of clinical innovations across the NSW public health system to change the way that care is delivered.

The ACI's clinical networks, institutes and taskforces are chaired by senior clinicians and consumers who have a keen interest and track record in innovative clinical care.

We also work closely with the Ministry of Health and the four other pillars of NSW Health to pilot, scale and spread solutions to healthcare system-wide challenges. We seek to improve the care and outcomes for patients by re-designing and transforming the NSW public health system.

Our innovations are:

- person-centred
- clinically-led
- evidence-based
- value-driven.

www.aci.health.nsw.gov.au



AGENCY FOR
**CLINICAL
INNOVATION**

*Our vision is to create the future of healthcare,
and healthier futures for the people of NSW.*